His primary research interest is in Hepatitis B virus (HBV) within a translational platform. He has a special interest in liver disease in young people, specifically HBV; he set up and runs the dedicated young adult liver service at The Royal London Hospital. He is widely published in viral liver disease and has almost 100 peer reviewed publications in addition to multiple book chapters and he has also edited a textbook of Gastrohepatology. His work in HBV is known internationally. He has produced novel work redefining disease phase and described clonal hepatocyte expansion and HBV DNA integration in young patients with HBeAg positive chronic infection (formerly referred to as “immune tolerant” patients), the foundation for the re-evaluation of treatment candidacy in Chronic Hepatitis B (CHB). He is a passionate advocate for early treatment (and broadening treatment access) in CHB to prevent disease progression and liver cancer. Developing these themes, an important focus of his current work is individualized treatment strategies for CHB, namely the early initiation of antiviral therapy and then access to novel therapies as part of the HBV functional cure program. Professor Kennedy is the chief/principal investigator for a number of investigator-led and commercial phase 1, 2 and 3, clinical trials in CHB and hepatitis delta virus (HDV). This clinical trial portfolio dovetails his longstanding research interest and publication record, the ultimate goal of which is achieving HBV cure.